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Abstract 
Background: 'HVSLWH1DPLELD¶VUREXVWPHGLFLQHXVHV\VWHPVDQGSROLFLHVDQWLELRWLFXVH
indicators remain suboptimal. Recent medicine use surveys rank cotrimoxazole, amoxicillin and 
azithromycin (CAA) among the most used medicines. However there is rising resistance to CAA 
(55.9% - 96.7 %). Unfortunately to date there have been limited studies evaluating policies to 
improve antibiotic use in Namibia. Aim: To evaluate public sector pharmaceutical policies and 
guidelines influencing the therapeutic use of CAA antibiotics in Namibia. Methods: Evaluate 
1DPLELD¶VSKDUPDFHXWLFDOSROLFLHVDQGJXLGHOLQHVIRU&$$XVHWKURXJKTXDQWLWDWLYHWH[W
analysis. The main outcome variables are existence of antibiotic policies, therapeutic indications 
per antibiotic and the type/level of health care facility allowed to use the antibiotic. Results: 
Policies for antibiotic use were limited with only the draft Namibia Medicines Policy having a 
statement on antibiotic use. Several essential antibiotics had no therapeutic indications 
mentioned in the guidelines. 29 antibiotics were listed for 69 therapeutic indications; CAA 
(49.3%) antibiotics and ATC J01C/J01D (48%) having the highest indications per antibiotic. For 
CAA antibiotics, this suggested use was mainly for acute respiratory infections (n=22, 37.2%). 
Published policies (58.6 % - 17/29) recommended antibiotics for use at the primary health care 
(PHC) level, with CAA antibiotics recommended mostly for respiratory tract infections and 
genitourinary infections. Conclusions: Policy and guidelines for antibiotic use in Namibia are 
not comprehensive and are skewed towards PHCs. Existing policies promote the wide use of 
CAA antibiotics, which may inadvertently result in their inappropriate use enhancing resistance 
rates. This calls for the development of more comprehensive antibiotic guidelines and essential 
medicine lists in tandem with local antimicrobial resistance patterns. In addition, educational 
initiatives among all key stakeholder groups.  
 
:KDW¶VNQRZQ 
x There is considerable overuse of common antibiotics across countries particularly in primary 
health care centres leading to increasing resistance rate 
x There are ongoing developments to improve the use of antibiotics across countries including 
general and specific guidelines treatment guidelines, essential medicine lists and quality 
indicators for antibiotics. In addition growing surveillance of antibiotic resistance patterns to 
guide the empiric use of antibiotics 
x However there can be concerns that the various groups producing prescribing guidance are 
not co-ordinated 
 
:KDW¶VQHZ 
x Novel way for low and middle income countries to assess utilization of common antibiotics 
against treatment guidelines, quality indicators and essential medicine lists especially where 
there are concerns with antibiotic resistance patterns 
x There appeared to be no co-ordination in Namibia between the various government bodies 
producing treatment guidelines, essential medicine lists and monitoring resistance patterns. 
As a result, continued high use of common antibiotics across multiple conditions 
exacerbating resistance rates 
x Several antibiotics were also listed in essential medicine lists but not included in any 
guidelines. This has implications for their misuse, which needs to be addressed 
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Introduction 
 
Inappropriate use of antibiotics increases antibiotic resistance leading to increases in morbidity, 
mortality and costs of treatment [1-5]. This is not helped by the fact that in most sub-Saharan 
countries, antibiotic treatment policies are not up-to-date, and there can be high rates of self-
purchasing of antibiotics, leading to increased antimicrobial resistance to essential antibiotics [6-
11] .  This has had a devastating impact on public health in the sub-Saharan Africa [12-16]. 
However, effective policies including education of all key stakeholder groups, prescribing 
restrictions as well as indicators have enhanced the appropriate use of antibiotics [14, 17-20]. 
 
In Namibia, despite the scale-up of medicine use systems and policies [Table 1; 12,21-30], 
antibiotic use and policy compliance indicators in the public health sector remain suboptimal [6, 
31-33]. As a result, there has been growing resistance to essential antimicrobials used among 
public health facilities in Namibia and sub-Saharan Africa; with a similar situation for anti-
malarials. These include chloroquine [34,35], cotrimoxazole [36-42 ], 
sulphadoxine/pyrimethamine [2] and ampicillin [43-46 ]. RHSRUWVIURPWKH1DPLELD¶V1DWLRQDO
Institute of Pathology (NIP) have also indicated increasing incidence of antibiotic resistance to 
first-line antibiotics particularly cotrimoxazole, azithromycin and amoxicillin (CAA), ranging 
between 55.9% - 96.7 % [36,39,47,48]. Despite the heightening resistance to CAA in Namibia, 
ABC analyses on expenditure of medicines and medicine use surveys at public health facilities in 
Namibia continue to rank CAA antibiotics among the top 15 expenditure items or top three 
antibiotics [6,21,32,49]. 
 
One of the factors driving increased prescribing of antibiotics in Namibia is the burden of 
infectious diseases particularly HIV/AIDS [6,32,33,36,39], which may well aggravate resistance 
to essential antibiotics [12,14,50]. One area of concern are the primary health care (PHCs) 
centers [32,51-56] with gaps in laboratory diagnostics, education regarding appropriate antibiotic 
use and human capacity [5,6,31]. Among PHCs, the risk of antibiotic misuse is exacerbated by 
the high workload for health workers with limited training on antibiotic pharmacotherapy as 
recommended by WHO and Medicines and related Act of Namibia [57-61]. In addition, only one 
indicator HF 13 regarding the number of antibiotics per prescription is used to monitor antibiotic 
use in Namibia. This currently only applying among public facilities including PHCs, district 
hospitals including state hospitals, intermediate hospitals that serve as regional referral hospitals 
and state hospitals that serve as national referral hospitals [25-29,62].  
 
Aims  
 
Consequently, we sought to address this by developing and evaluating antibiotic use indicators at 
policy level in Namibia as the first step to improve future antibiotic use in ambulatory care in 
Namibia. Box 1 contains details of the current systems and policies in Namibia. 
 
Box1: Systems and policies for medicine use in Namibia 
 
Pharmaceutical Systems in Namibia: 
x Pharmaceutical Management information system (PMIS): A system implemented in all 
hospital and public health facility for reporting on performance and monitoring human 
resources for pharmacy and medicine indicators. This is implemented by the Ministry of 
Health and Social Services ± Pharmaceutical division 
x Electronic data base system: including the electronic dispensing tool, the stock card 
Dashboard, the TB manager and the Rx solution to collect monthly data on the use of 
medicines at public health facility 
x System for access to essential medicines: An updated Namibia essential medicine list 
provides for the level of use of various medicines  which all accessed free at public health 
facilities 
Policies:  
x Namibia Medicine policy: provide a frame work for access and availability to safe, 
efficacious and cost effective medicines to the population and the rational use of 
medicines. 
x Pharmacy Act, 2004: provides for the education and qualifications as well as continued 
professional development of personnel involved in the use of medicines in Namibia 
x Medicines and related substances act of 2003: provides for the control of the use,  
distribution and sale of medicines in Namibia and categorizes medicines in schedules 
x Standard treatment guidelines: for implementation of policies at points of care for 
common medicines , HIV/AIDS, Tuberculosis , Malaria and management of childhood 
illnesses 
x Essential medicine list: ensures the access and availability of essential medicines at public 
health facilities 
 
 
Materials and methods 
 
Medicine policy documents 
 
We searched the Ministry of Health and Social services (MoHSS) websites and government of 
Namibia websites for policy documents relating to pharmaceuticals that were developed between 
1990 to 2015. The search strategy included the use of terms such as ³SROLF\PHGLFLQHJXLGHOLQH
$FWODZVUHJXODWLRQVDQG1DPLELD´ The most recent editions of all policy documents in the 
MoHSS database on Pharmaceutical services division were included in this study.  
 
A total of seven policy documents were identified as up-to-date and pertinent pharmaceutical 
policy documents and were analyzed for content on antibiotic policy statements.   The Namibia 
essential medicine list (Nemlist) [22] was used as the defining document for assessing antibiotic 
XVHLQ1DPLELD¶VSXEOLFKHDOWKVHFWRU. The Nemlist is critical with implementing the national 
medicine policy through defining the range of essential medicines recommended for use at 
different levels of the public sector. The Nemlist is also a critical document to operationalize 
treatment policies and guidelines. The Namibian standard treatment guidelines (2011) [23], the 
national guidelines for management of HIV/AIDS (2015) [24], the national guidelines for 
management of tuberculosis (2015) [25], the guidelines for management of malaria (2011) [26] 
and for integrated management of childhood illnesses (2012) [27], were used as the principal 
documents from which indications for essential antibiotics in the Nemlist were reviewed.  
 
The Pharmacy Act (2004) [29], the Medicines related substance Act (2003) [30], and the draft 
National medicine policy [28] were used as reference documents in the analysis. These Acts of 
parliament that regulate the use of medicines and pharmacy professionals were used to identify 
laws supporting the judicious use of antibiotics in the health care sector of Namibia. Both Acts 
and the national medicine policy provide an overarching legal frame work for policies on 
medicine use including antibiotic in Namibia. 
 
Methods 
 
Quantitative policy analysis methods were used to evaluate pharmaceutical policy indicators for 
antibiotic use [63]. A document analysis design was subsequently used to analyse the content of 
the LGHQWLILHGSROLFLHVIRUDQWLELRWLFXVHLQ1DPLELD¶VSXEOLFKHDOWKFDUH. The Nemlist was used as 
the defining document for the analysis of antibiotic use in Namibia by the health care facility 
level, for vital, essential and necessary medicines (VEN) classification of medicines [22] and 
formulations.  The treatment guidelines were subsequently used as asserting documents for 
content analysis on the use of Nemlist antibiotics by indication and prescriber.  
 
7KHVHDUFKVWUDWHJ\LQFOXGHGWKHXVHRIVHDUFKWHUPVDV³infection, inflammation, itis, and acute, 
chronic, bacterial, viral, fungal, and protozoa and/or parasitic´WRLGHQWLI\LQGLFDWLRQVIRU
DQWLELRWLFVDQGRU&$$6HDUFKHGWHUPVLQFOXGLQJ³antibiotic, cotrimoxazole, amoxicillin, 
D]LWKURP\FLQDQGDQWLQIHFWLYHV´ were used to identify the antibiotics within the treatment 
guidelines and analyse the indications. The medicine regulations and laws were used as reference 
documents, and were reviewed for policy statements on antibiotic use. The main outcome 
variables were policy statements on antibiotic use, indications per antibiotic on the essential 
medicines list and factors associated with antibiotic use.  The data were abstracted on a 
developed form and entered into SPSS v21 software for quantitative analysis.   
 
Ethical considerations 
The study has no ethical implications as no human subjects were interviewed or recruited in this 
study. The study adopted a policy document analysis approach where secondary data was used 
from policy documents which are all accessible for use by the public. All extracts from the 
policy documents have been referenced.  
 
Results 
 
Policy indicators for antibiotic use 
Only the HF-13 indicator is currently used to measure antibiotic use in Namibia [49] at the health 
facility level. Five policy indicators for measuring effective and safe antibiotic use were 
developed based approaches by Brown [64] and evaluated (Table 1). These indicators assessed 
the implementation of antibiotic policies across sectors. They were developed based on access, 
availability and use of antibiotics as described by the Namibian medicine policy statements for 
the general use of medicines. These indicators focus on both access and availability of antibiotic 
policy documents at the National level and their implementation at the points of access of 
antibiotics. 
 
Table 1: Policy indicators for antibiotic use 
 
Policy indicator Thresh hold 
 
Status 
 
Availability and access to key antibiotic policy documents  
% of policy documents with policies on antibiotic use 
Available of a  comprehensive antibiotic policy  
# Antibiotic policy statements in the National Medicines Policy 
#Antibiotic treatment documents: guideline, formulary 
Availability of an antibiogram / surveillance policy 
 
 
100% 
100% 
100% 
100% 
100% 
 
1/7 
_ 
_ 
_ 
_ 
# of indications per antibiotic 
Average # of indications per ATC class J01C and J01D 
Average # of indications per top ABC antibiotics 
# of antibiotics by body systems (empiric therapy) 
%  antibiotics in Nemlist with indications in STG 
 
25% 
25% 
50% 
100% 
 
 
 
 
9/11(75%) 
Levels of use of an antibiotic   
% of antibiotics for use at PHC level 
% of  with restricted use by specialist 
% of antibiotics used for prophylaxis therapy 
% of antibiotics indicated for URTI 
50% 
50% 
50% 
10% 
100% 
100% 
2  
 
 
Current antibiotic policies in Namibia 
A total seven policy documents were reviewed for policies on antibiotic use. The majority were 
treatment guidelines 42.9 % (3/7), with only the draft National Medicine Policy14.3% (1/7) 
having a policy statement on antibiotic use; ³7KHQHHGIRUUDWLRQDOXVHKROGVJRRGIRUDOO
medicines, but it is especially necessary in certain situations, e.g.: i. the use of antibiotics, where 
reckOHVVXVHZLOOSURPRWHWKHGHYHORSPHQWRIDQWLPLFURELDOUHVLVWDQFH´Currently, Namibia has 
no policy document specific to antibiotic use; no medicines or antibiotic formulary and no 
antibiograms to guide antibiotic use. A total of 29 antibiotics are incluGHGLQ1DPLELD¶VHVVHQWLDO
medicine list; 3 of which have no indications in the standard treatment guidelines (Figure 1). 
Overall, the treatment guidelines include 69 indications for antibiotic use.  
 
The Medicines and related substances control Act, 2003 categorizes most antibiotics as 
prescription only medicines and categorizes them as schedule 2 medicines. Cotrimoxazole, 
amoxicillin and azithromycin are classified as essential and vital and cotrimoxazole as essential. 
 
Clarithromycin is indicated for two infections in the treatment guideline but not listed in the 
essential medicine list. HIV/AIDS and TB treatment policies provide for the use of 
cotrimoxazole as preventive therapy (CPT) in all HIV positive children and lifelong use in adults 
unless there are contraindications.  Treatment polices in the HIV/AIDS treatment guidelines 
however recommend that the use of CPT in adults can be discontinued if two consecutive CD+4 
counts are consistently above 350 cells /mm3.  
 
Patterns of indications for antibiotic use by treatment policies guidelines  
The majority of the antibiotics in the treatment policies and guidelines are ȕ-lactam antibiotics 
(48.0%) - ATC class J01C and J01D and for use at the PHC level (58.6%). There is a 
significantly higher number of antibiotics indicated for treatment of oral/dental infections (p < 
0.001), CNS infections (p < 0.041), HIV/AIDS related illnesses (p = 0.005) and the management 
of eye and ear infections. Both parenteral and oral forms of antibiotics are indicated or use at the 
PHC level (Table 2).  
 
  
Table 2: Characteristics of antibiotics in the treatment guidelines (n = 29) 
 
 Number (%) df F2 p ± value* 
 
ATC class of the antibiotic 
J01 A 
J01 B 
J01 C 
J01 D 
J01 E 
J01 F 
J01 G 
J01 M 
J01 X 
 
1(3.4) 
1(3.4) 
9(31) 
5(17.0) 
1(3.4) 
4(13.8) 
3(10.3) 
2(6.9) 
3(10.3) 
 
7 
 
14.310 
 
0.046 
Antibiotic formulation 
Oral 
Parenteral 
Oral and parenteral 
 
12 (41.4) 
12 (41.4) 
5(17.2) 
 
2 
 
3.38 
 
0.185 
Indicated for use at PHC 
Yes 
No 
Both 
 
12 (41.4) 
14(48.3) 
3(10.7) 
 
2 
 
7.103 
 
0.000 
ATC class of CAA antibiotics 
Yes 
No 
 
3(10.7) 
26(37.7) 
 
2 
 
18.241 
 
0.000 
Antibiotics indicated by policy 
Essential medicine list  
Treatment guidelines 
Malaria policy 
HIV treatment guideline 
Tuberculosis guideline 
 
28(96.6) 
28(96.6) 
2(6.9) 
4(13.8) 
2(6.8) 
 
2 
 
2 
2 
2 
 
25.138 
21.552 
21.552 
15.207 
21.552 
 
0.000 
0.000 
0.000 
0.000 
0.000 
%  Antibiotics per infection 
Respiratory infection  
Genitourinary infection 
Musculoskeletal disorders 
Oral and dental infections  
CNS infections  
HIV disorders  
Gastrointestinal disorders  
Prophylaxis in Malnutrition   
Ear and Eye infections 
Obstetric infections 
Septicaemia/ Malaria 
 
15(51.7)  
12(41.4 
14(48.3) 
3(10.3) 
9(31.0) 
7(24.1) 
10(34.5) 
5(17.5%) 
8(6.9) 
2(6.9) 
10(34.5) 
 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
 
0.034 
0.862 
0.034 
18.241 
4.172 
7.759 
2.793 
12.448 
5.828 
21.552 
2.793 
 
0.853 
0.353 
0.853 
0.000 
0.041 
0.005 
0.095 
0.000 
0.016 
0.016 
0.095 
*NPar Chi-square test 
  
Treatment policy indications per antibiotic  
Out of the 29 essential antibiotics, amoxicillin, azithromycin and metronidazole have the most 
indications per antibiotic, three antibiotics have no indications in the treatment guidelines and 
cotrimoxazole is the main antibiotic used in HIV/AIDS for preventive therapy (Figure 1). 
Phenoxymethylpenicillin, a limited spectrum penicillin, is indicated for infections other than 
pharyngitis / tonsolitis.  CAA antibiotics are indicated for approximately half of the indications. 
 
Figure 1:  Number of treatment indications per antibiotic (n = 69) 
 
 
 
 
  
34(49.3%)
21(30.4)
20(29%)
20(29%)
14(20.3%)
13(18.8%)
12(17.45)
10(14.4%)
9(13%)
8(11.6%)
8(11.6%)
7(10.1%)
7(10.1%)
6(8.7%)
4(5.8%)
4(5.8%)
3(4.3%)
3(4.3%)
3(4.3%)
2 (2.9%)
2(2.9%)
2(2.9%)
2(2.9%)
2(2.9%)
1(1.5%)
1(1.5%)
1(1.5%)
0
0
0
CAA Antibiotic
Azithromycin
Amoxycillin
Metronidazole
Erythromycin
Gentamicin
Ceftriaxone
Doxycycline
Cloxacillin
Ampicillin
Clindamycin
Benzylpenicillin
Chloramphenicol
Cefuroxime
Ciprofloxacin
Cefixime
Benzathine Benzylpenicillin
Procaine Penicillin
Phenoxymethylpenicillin
Nalidixic Acid
Nitrofurantoin
Clarithromycin
Co-trimoxazole
Amikacin
Fusidic Acid
Cefalothin
Streptomycin
Cefradine
Piperacillin + Tazobactam
Benzyl +Benzathine+ procaine penicillin
Factors associated with indications for CAA antibiotics  
Treatment policies indicated the prescribing of CAA antibiotics for the treatment of respiratory, 
musculoskeletal, gastrointestinal and genitourinary infections.  Policies recommend the use of 
CAA antibiotics for a wide range of systemic conditions, prophylaxis in HIV/AIDS, malnutrition 
(Table 3).  
 
Treatment policies are more likely to indicate the use CAA antibiotics at the PHC rather than 
hospital level [OR 35.75(95% CI; 4.21±303.42), p < 0.001].    
 
 
Table 3: Indication for CAA antibiotics 
 
Characteristic Mean indications (± SD) F 95%CI p-value 
CAA  Not CAA 
Respiratory infection 6±5.29 0.92±1.197 31.7 2.769 ± 7.384 0.000 
Genitourinary infect 2 ±3.464 1 ±1.356 11.83 -1.014 ± 3.014 0.002 
Musculoskeletal  infec 2.33±2.51 1.27±2.09 0.122 -1.593 ± 3.721 0.729 
Oral/Dental infections 1.00±1.732 .15± .613 10.053 -0.098 ± 1.791 0.004 
CNS infection .33± .577 .31 ±.471 0.028 -0.574 ± 0.625 0.869 
HIV/AIDS infections .67± .577 .31 ±.679 0.039 -0.482 - 1.2 0.845 
Gastrointestinal 
infections 
.67 ±.577 .54 ±1.104 0.409 -1.215 ± 1.472 0.528 
Malnutrition therapy .33 ±.577 .15± .368 1.451 -0.305- 0.664 0.239 
Ear and eye infection 1.00 ±1.000 .31± .618 0.620 -1.216 ± 1.510 0.438 
Obstetrics and 
Gynaecology 
infections 
0.00± 0.00 .08 ±.272 1.108 -0.404 ± 0.250 0.302 
Septicaemia/Malaria 0.00± 0.000 0.42±0.578 15.187 1.717 ± 16.027 0.001 
NB: Levene's Test for Equality of Variances; CI = 95% Confidence interval 
 
The standards in the STGs criteria for use of CAA antibiotics  
Azithromycin and amoxicillin are selectively indicated for treatment of 90% of respiratory tract 
infections in the STGs; including upper respiratory infections that are commonly of a viral 
aetiology [61] and to manage secondary bacterial infections [23].  Cotrimoxazole is 
recommended for prophylaxis against PCP and other types of pneumonia in HIV/AIDS patients. 
 
Discussion 
 
Despite the existence of guidelines for antibiotic use in various treatment guidelines in Namibia 
including HIV/AIDS, malaria, and tuberculosis as well as the integrated management of 
childhood illnesses in Namibia [22-27] (Table 1), Namibia has no comprehensive antibiotic 
policy, antibiotic guidelines, antibiotic formulary or antibiograms. These strategies provide the 
evidence based for the appropriate use of antibiotics [10, 45, 60, 62, 65,66].  Previous studies in 
Namibia on antibiotic use have recommended the development of guidelines specific to 
antibiotics in both the private and public sectors [6,31-33]. Unfortunately to date, only the draft 
National medicine policy has a policy statement on antibiotics which is mentioned in a passive 
way [29]. 
 
Approximately half of the antibiotics indicated in the treatment policies are of ATC classes J01 
'DQG-&ȕ-lactam) and / or CAA antibiotics (Table 2 and Figure 1). Medicine use surveys 
across all sectors in Namibia have implicated the overuse of penicillins and macrolides 
particularly for upper respiratory tract infections (URTIs) and common community acquired 
diseases [6,33]. The rate of antibiotic utilisation was estimated at 78% for all URTIs and 48% for 
all other infections in the public sector despite their origin [6,33]. The Pharmaceutical 
Management Information System (PMIS) data indicates that only two regions in Namibia 
currently meet the HF-13 indicator for antibiotic use [49]. National and regional ABC analyses 
that categorize medicine consumption by expenditure in Namibia continue to indicate CAA and 
ȕ-lactam antibiotics among the most used medicines [32,49,62]. We also found that 
phenoxymethylpenicillin, an ATC J01C antibiotic, is indicated for several infections despite its 
QDUURZVSHFWUXPDJDLQVW*$ȕHS that causes tonsillitis and pharyngitis. Studies conducted in 
Greece [67,68] , Libya [69] , Egypt [69] and Nigeria [70-72] report rates of penicillin use 
between 15.5 % - 54% with amoxicillin, co-Amoxiclav®, ampicillin and cloxacillin the most 
used  penicillins. Macrolides use is estimated at14.5 %, which includes the use of azithromycin, 
erythromycin and clarithromycin. The medicine policies in Namibia may be influencing the high 
use of CAA antibiotics at health facilities as the medicines that are highly used are the medicines 
with the highest number of indications per antibiotic and used at all levels and all prescribers as 
well as in prophylactic programmes [Table 1; Figure 1; 6]. The over use of CAA antibiotics due 
to policy indications may cause selective pressure for antimicrobial resistance, and irrational 
practices may exacerbate the problem [2,4,6,12]. Sensitivity reports have reported a rising 
resistance to CAA ranging between 58 ± 95.6% [4, 31].  This needs to be addressed to enhance 
the effectiveness of these important antibiotics. This includes addressing suboptimal adherence 
to good prescribing practices that have been reported in medicine use surveys in Namibia and 
addressing poor indicators of good antibiotic prescribing such as number of antibiotics per 
prescription, which is currently seen as to high in Namibia across all sectors [6,32,33,49].  
 
In addition, three antibiotics (10%) on the essential medicine list have no indications in the 
treatment guidelines (Figure 1).  Two antibiotics contained in treatment guidelines ± 
clarithromycin and dapsone - are not listed on the essential medicines list. The lack of 
concurrence between the essential medicines list and the treatment guidelines may lead to 
inappropriate use and limited access of antibiotics.  This needs to be resolved.  
 
In Namibia, there are also currently two committees for the essential medicines list and treatment 
guidelines, which work in parallel. This may lead to policy duplication or omissions, both 
potentially causing negative consequences on access and therapeutic outcomes [22, 23]. This 
again needs to be looked at to improve future antibiotic use. 
 
This study found that medicine policies indicate all the CAA antibiotics for use at all levels of 
health care in Namibia including primary health care (Table 1) for both curative and preventative 
programmes. In primary health care, cotrimoxazole is indicated for HIV/AIDS related infections 
and amoxicillin in presumptive prophylaxis in malnutrition. Overall, CAA antibiotics are 
indicated for use in 75% (9/11) of indications by body systems with the respiratory, 
genitourinary and musculoskeletal disorders systems have the most indications for CAA 
antibiotics. The wide number of indications of CAA antibiotics by level of health care and 
disease is a risk factor for overuse and the development of AMR [52,56,60,68,73-75], with 
misuse linked to limited prescriber and diagnostic capacity as well as pressure from patients 
[43,51,52,54, 61]. In Namibia, with the current human resource issues, nurses are the main 
prescribers at the lower levels of care, e.g. PHCs, where antibiotic prescribing is mainly empiric. 
In addition, compliance to STGs is estimated to be between 48 ± 75% [23,32,33]. Whilst this 
appears similar to public health settings studies across countries, this needs to be improved 
[13,15,43,67,76].   
 
In Lesotho [7] 57.8% of the antibiotics prescriptions did not comply with the National standard 
treatment guidelines. A study by Shiva et al. [15] reported that 69.6% of the prescribers do not 
comply with guidelines and formularies on the basis of right antibiotic indication, dose and 
duration.  This may be due to issues of lack of knowledge regarding appropriate antibiotic 
prescribing with physicians in a recent systematic review requesting educational input to 
improve their prescribing [43]. 
 
Medicine policies and guidelines in Namibia currently indicate the use of CAA antibiotics for 
most respiratory; urogenital; musculoskeletal and gastrointestinal infections; disease conditions 
that are highly prevalent at PHCs in Namibia [Table 3; 22-27].  The study by Kunda [37] 
indicates high use of antibiotics in URTIs of up to 78% in Namibia, which needs to be addressed 
given the high percentage of URTIs that are viral in origin. Cotrimoxazole is indicated for 
management of bloody diarrhea. However the NIP antibiogram shows up to 90% resistance 
levels of most bacteria common in respiratory and urinary tract infections such as S. aureus, S. 
pneumoniae and E.coli to amoxicillin and cotrimoxazole [47]. Consequently, there is a need to 
revise the guidelines as well as instigate policies that reduce resistance rates to these effective 
antibiotics. The latter potentially including extensive educational initiatives including patients. 
 
Conclusions and recommendations  
 
Policy indicators for antibiotic use are suboptimal in Namibia and may be an important driver in 
the current overuse of CAA antibiotics in Namibia. Overall, Namibia currently lacks a 
comprehensive antibiotic policy and up-to-date guidelines, formulary and antibiograms. This 
may negatively impact on evidence based empiric therapy at all levels of care, which is a 
concern given current high resistance rates to CAA antibiotics.  
 
There are also concerns with the lack of coherence between the Nemlist and STGs, with some of 
the antibiotics listed in the EML having no indications in STGs. Treatment guidelines also 
currently have a high number of indications per antibiotics for CAA and ATC class J01C 
antibiotics. This needs to be urgently addressed. Medicine policies in Namibia are an important 
factor that currently promotes the wide use of CAA antibiotics by level of health care and by 
disease. Alongside this, current antibiotic indications are not in tandem with NIP resistance 
reports and may lead to the loss of sensitivity to essential antibiotics such as CAA antibiotics.    
 
Consequently, it is recommended that the authorities in Namibia urgently develop a 
comprehensive antibiotic policy, including the harmonization of policy documents, to improve 
antibiotic use at all levels of health care, particularly at PHCs where human resource capacity is 
currently a problem. The antibiotic guidelines should be revised to parallel local resistance 
patterns.  As a result, we recommend the development of a compressive antibiotic guideline, 
based on annual antibiograms, and with agreed quality indicators to improve future antibiotic 
use. This alongside additional education for all key stakeholder groups, especially PHC 
personnel, to improve future antibiotic prescribing.  
 
We also believe our methodology of combining an analysis of current policy documents 
including formularies, antibiotic prescribing behavior and resistance patterns is applicable to 
other lower and middle income countries as they strive to improve their antibiotic use. We will 
be monitoring developments in Namibia in the future as part of continuing research activities in 
this critical area. 
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